Compare UNCY & QIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | QIPT |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 157.2M |
| IPO Year | 2021 | N/A |
| Metric | UNCY | QIPT |
|---|---|---|
| Price | $6.21 | $3.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $44.50 | $3.83 |
| AVG Volume (30 Days) | ★ 700.0K | 534.5K |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $245,359,000.00 |
| Revenue This Year | N/A | $28.30 |
| Revenue Next Year | N/A | $1.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.71 | $1.35 |
| 52 Week High | $11.00 | $3.61 |
| Indicator | UNCY | QIPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 70.62 |
| Support Level | $6.12 | $3.55 |
| Resistance Level | $6.94 | $3.54 |
| Average True Range (ATR) | 0.52 | 0.02 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 45.21 | 40.00 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Quipt Home Medical Corp is a provider of durable medical equipment (DME) and home medical equipment (HME) in the United States. The Company specializes in delivering in-home treatments for the management of chronic conditions, with a primary focus on respiratory diseases, and supports patients with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Its products and services include Sleep Apnea and PAP treatment, home medical equipment, home ventilation, and custom mobility solutions. The Company operates in a single business segment, comprising the sale and rental of medical equipment and related devices, and serves patients across 27 states in the United States.